- Home
- RS vs IKT Comparison
RS vs IKT Comparison
Compare RS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RS | IKT |
|---|---|---|
| Founded | 1939 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9B | 201.3M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RS | IKT |
|---|---|---|
| Price | $295.58 | $2.02 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $317.25 | $6.00 |
| AVG Volume (30 Days) | 328.3K | ★ 570.5K |
| Earning Date | 10-22-2025 | 11-14-2025 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 13.63 | N/A |
| Revenue | ★ $13,922,300,000.00 | N/A |
| Revenue This Year | $5.83 | N/A |
| Revenue Next Year | $4.35 | N/A |
| P/E Ratio | $21.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $250.07 | $1.33 |
| 52 Week High | $347.44 | $3.49 |
Technical Indicators
Market Signals| Indicator | RS | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 62.30 | 71.78 |
| Support Level | $289.23 | $1.56 |
| Resistance Level | $298.49 | $2.05 |
| Average True Range (ATR) | 5.73 | 0.16 |
| MACD | 0.34 | 0.04 |
| Stochastic Oscillator | 76.91 | 94.35 |
Price Performance
Historical ComparisonAbout RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.